Fortress Biotech, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US34960Q3074
USD
2.75
0.18 (7.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Fortress Biotech, Inc. stock-summary
stock-summary
Fortress Biotech, Inc.
Pharmaceuticals & Biotechnology
Fortress Biotech, Inc.(Fortress) is a biopharmaceutical company that acquires, develops and commercializes novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.
Company Coordinates stock-summary
Company Details
2 Gansevoort St Fl 9 , NEW YORK NY : 10014-1667
stock-summary
Tel: 1 781 65245001 781 6524500
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 8 Schemes (3.96%)

Foreign Institutions

Held by 9 Foreign Institutions (2.18%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Lindsay Rosenwald
Executive Chairman of the Board, President, Chief Executive Officer
Dr. Eric Rowinsky
Co-Vice Chairman and Director
Mr. Michael Weiss
Executive Vice Chairman - Strategic Development, Director
Dr. Jimmie Harvey
Independent Director
Mr. Malcolm Hoenlein
Independent Director
Mr. Dov Klein
Independent Director
Mr. J. Jay Lobell
Independent Director
Mr. Kevin Lorenz
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
16 Million
(Quarterly Results - Jun 2025)
Net Profit:
-12 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 107 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.42

stock-summary
Return on Equity

-210.42%

stock-summary
Price to Book

2.44